Trials / Completed
CompletedNCT02574390
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,049 (actual)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples (blood and spinal fluid (optional)), and cell lines for ALS gene identification. This will be combined carefully with collected measures of the pattern of the symptoms people with ALS have and how these change over time. People with other motor neuron diseases and healthy controls will be included as comparisons
Detailed description
Patients will have 5 study visits; screening, 3, 6, 9 and 12 months. There will be a one year post-participation follow-up period, during which they will receive an email or phone call interview once every 3 months. During the first year, samples will be collected, breathing, muscle strength, spasticity, general function and cognitive behavior will be assessed. Healthy controls will have 2 study visits during which blood samples will be collected and questionnaires given.
Conditions
- Amyotrophic Lateral Sclerosis
- Primary Lateral Sclerosis
- Flail Arm ALS
- Progressive Muscular Atrophy
- Monomelic Amyotrophy
- Motor Neuron Disease
- Asymptomatic ALS Gene Carriers
- Healthy Controls
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2019-12-31
- Completion
- 2020-01-01
- First posted
- 2015-10-12
- Last updated
- 2020-01-13
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02574390. Inclusion in this directory is not an endorsement.